Investigating how targeting the Ninjurin pathway can help tumors with normal p53 function
The Mechanism and Therapeutic Potential of Targeting the Ninjurin Pathway for Tumors Carrying Wild-Type p53
This study is looking at how certain proteins called Ninjurin work with a key cancer-fighting protein, p53, to see if understanding their relationship can help develop new treatments for tumors that still have normal p53 function, which could ultimately benefit patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California at Davis NIH-funded |
| Lab location | 1 site (Davis, United States) |
| Project ID | NIH-10850558 on NIH RePORTER |
What this research studies
This research explores the role of the Ninjurin proteins in cancer, particularly in tumors that have normal p53 function. It aims to understand how these proteins interact with p53 and affect tumor growth and spread. By studying the mechanisms behind this interaction, the research seeks to identify new therapeutic strategies that could inhibit tumor progression. Patients may benefit from insights that could lead to innovative treatments targeting these pathways.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with tumors that have normal p53 function, particularly those with breast cancer.
Not a fit: Patients with tumors that have mutated p53 may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that improve outcomes for patients with tumors carrying wild-type p53.
How similar studies have performed: Previous research has shown promising results in targeting similar pathways in cancer treatment, suggesting potential for success in this approach.
Where this research is happening
Davis, United States
- University of California at Davis — Davis, United States (Active)
Researchers
- Principal investigator: Chen, Xinbin — University of California at Davis
- Study coordinator: Chen, Xinbin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.